Overhaul recommended for gene-therapy review
December 5, 2013
The US National Institutes of Health (NIH) should refocus its oversight of gene-transfer research, the US Institute of Medicine (IOM) says in a report released today. The analysis concludes that the NIH’s Recombinant DNA Advisory Committee, or RAC, should no longer review most gene-therapy research. But there are some areas that it says the RAC should still oversee — such as studies that involve new gene-transfer vectors or that pose particular safety worries. The panel adds that the NIH should also give the committee a broader remit to review any kind of emerging research in humans that deserves special scrutiny because it raises safety or ethical issues. (Nature)